Trial · NCT03332589
Adverse events81
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
21 to 40 of 81
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Gait disturbance | General disorders | Expansion: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Hyperbilirubinaemia | Hepatobiliary disorders | Monotherapy Safety Run-in: E6201 | 1 | 4 | 1 |
| other | Hyperbilirubinaemia | Hepatobiliary disorders | Combination Safety Run-in: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Hyperbilirubinaemia | Hepatobiliary disorders | Expansion: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Respiratory tract infection | Infections and infestations | Monotherapy Safety Run-in: E6201 | 1 | 4 | 1 |
| other | Respiratory tract infection | Infections and infestations | Combination Safety Run-in: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Respiratory tract infection | Infections and infestations | Expansion: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Rhinitis | Infections and infestations | Monotherapy Safety Run-in: E6201 | 1 | 4 | 1 |
| other | Rhinitis | Infections and infestations | Combination Safety Run-in: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Rhinitis | Infections and infestations | Expansion: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Sepsis | Infections and infestations | Monotherapy Safety Run-in: E6201 | 2 | 4 | 2 |
| other | Sepsis | Infections and infestations | Combination Safety Run-in: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Sepsis | Infections and infestations | Expansion: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Hypokalaemia | Metabolism and nutrition disorders | Monotherapy Safety Run-in: E6201 | 3 | 4 | 3 |
| other | Hypokalaemia | Metabolism and nutrition disorders | Combination Safety Run-in: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Hypokalaemia | Metabolism and nutrition disorders | Expansion: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Dizziness | Nervous system disorders | Monotherapy Safety Run-in: E6201 | 1 | 4 | 1 |
| other | Dizziness | Nervous system disorders | Combination Safety Run-in: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Dizziness | Nervous system disorders | Expansion: E6201 Plus Dabrafenib | 0 | 0 | 0 |
| other | Neuropathy peripheral | Nervous system disorders | Monotherapy Safety Run-in: E6201 | 1 | 4 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03332589/events?page=2